
    
      The study is to evaluate the efficacy and safety of two doses of xiangjurupining capsule,give
      three times a day versus placebo in Hyperplastic disease of breast patients .The clinical
      phase of the study comprises a run-in period，an 3-months double-blind treatment period and a
      1-month follow-up period, resulting in 5-months overall duration of the study for each
      patient.

      Patients report their breast pain as measured using NRS scale on the subject daily diary。
    
  